We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants.
- Authors
Jansen, Mark; Schuldt, Maike; van Driel, Beau O.; Schmidt, Amand F.; Christiaans, Imke; van der Crabben, Saskia N.; Hoedemaekers, Yvonne M.; Dooijes, Dennis; Jongbloed, Jan D. H.; Boven, Ludolf G.; Deprez, Ronald H. Lekanne; Wilde, Arthur A. M.; Jans, Judith J. M.; van der Velden, Jolanda; de Boer, Rudolf A.; van Tintelen, J. Peter; Asselbergs, Folkert W.; Baas, Annette F.
- Abstract
Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disease, commonly caused by pathogenic MYBPC3 variants, and a significant cause of sudden cardiac death. Severity is highly variable, with incomplete penetrance among genotype-positive family members. Previous studies demonstrated metabolic changes in HCM. We aimed to identify metabolite profiles associated with disease severity in carriers of MYBPC3 founder variants using direct-infusion high-resolution mass spectrometry in plasma of 30 carriers with a severe phenotype (maximum wall thickness ≥20 mm, septal reduction therapy, congestive heart failure, left ventricular ejection fraction <50%, or malignant ventricular arrhythmia) and 30 age- and sex-matched carriers with no or a mild phenotype. Of the top 25 mass spectrometry peaks selected by sparse partial least squares discriminant analysis, XGBoost gradient boosted trees, and Lasso logistic regression (42 total), 36 associated with severe HCM at a p < 0.05, 20 at p < 0.01, and 3 at p < 0.001. These peaks could be clustered to several metabolic pathways, including acylcarnitine, histidine, lysine, purine and steroid hormone metabolism, and proteolysis. In conclusion, this exploratory case-control study identified metabolites associated with severe phenotypes in MYBPC3 founder variant carriers. Future studies should assess whether these biomarkers contribute to HCM pathogenesis and evaluate their contribution to risk stratification.
- Subjects
HYPERTROPHIC cardiomyopathy; METABOLOMICS; HYPERTROPHIC scars; VENTRICULAR arrhythmia; INDUCTIVELY coupled plasma mass spectrometry; CONGESTIVE heart failure; CARDIAC arrest; VENTRICULAR ejection fraction
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 4, p4031
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms24044031